12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

K-Ras and BRAF mutation screening diagnostic data

Researchers at the foundation reported data from a simulated cost-effectiveness analysis showing that screening for K-Ras mutations prior to starting treatment with cetuximab saves about $7,500 over 10 years in mCRC patients compared with no screening ($57,348 vs. $64,841). However, the researchers found that the incremental cost effectiveness ratio (ICER) per LYS gained with screening is still above "the generally accepted threshold" of an acceptable cost-effectiveness ratio. Screening for K-Ras mutations prior to starting treatment with cetuximab had an ICER per LYS of $2,814,338 vs. $2,932,767 for cetuximab treatment without screening for K-Ras mutations. The researchers also estimated...

Read the full 470 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >